Graver Christopher, Green Paul
Madigan Army Medical Center, MCHJ-CLU-CP, Tacoma, WA, USA.
Green's Publishing, Kelowna, BC, Canada.
Appl Neuropsychol Adult. 2022 May-Jun;29(3):315-323. doi: 10.1080/23279095.2020.1748035. Epub 2020 May 12.
Loring and Goldstein presented a case of a woman with Multiple Sclerosis (MS) who failed the traditional performance validity criteria of the WMT. Scoring lower than the mean from patients with Alzheimer's Disease on extremely easy subtests, the patient carried on to produce a WMT profile which is typical of someone with invalid test results, based on the usual interpretation, which is standardized within the Advanced Interpretation Program. Statements were made that are incorrect, including the claim there are no available data on the WMT in MS patients, that the minor tranquilizer Lorazepam can explain WMT failure even in healthy adults and that this patient produced a neuropsychological profile that is credible and typical of MS. We report data from MS patients given comprehensive neuropsychological assessment, including the WMT. Loring and Goldstein's interpretation of this case does not fit the facts.
洛林和戈尔茨坦介绍了一例患有多发性硬化症(MS)的女性病例,该患者未通过韦氏记忆测验(WMT)的传统成绩效度标准。在极其简单的子测验中,该患者的得分低于阿尔茨海默病患者的平均分,根据在高级解释项目中标准化的通常解释,该患者得出了一个典型的测验结果无效者的WMT剖面图。文中做出了一些错误陈述,包括声称没有关于MS患者WMT的可用数据、声称即使在健康成年人中,小剂量镇静剂劳拉西泮也能解释WMT失败,以及声称该患者得出了一个可信的、典型的MS神经心理学剖面图。我们报告了对MS患者进行全面神经心理学评估(包括WMT)的数据。洛林和戈尔茨坦对该病例的解释不符合事实。